Why the study?
Does lovastatin therapy improve gangrenous lesions in a patient with blue toe syndrome?
Does lovastatin therapy improve gangrenous lesions in a patient with blue toe syndrome?
Lovastatin therapy may serve as an effective conservative treatment for reversing gangrenous lesions in blue toe syndrome caused by atheromatous emboli.
Answers are grounded in this paper and cite their sources.
May support lovastatin for gangrenous lesions in blue toe syndrome; hypothesis-generating and leaves open need for controlled trials.
A seventy-six-year-old man with ischemic heart disease, peripheral vascular disease, and chronic renal failure developed bilateral cyanotic toes, which upon muscle biopsy, were shown to be caused by atheromatous emboli. The probable source was atheromatosis of the abdominal aorta. The toes became gangrenous, but surgical therapy was deferred because the patient was considered a high risk. With lovastatin therapy there was complete healing and except for transient cyanosis related to temporary cessation of therapy, there has been no recurrence for the past thirty months. The possible role of lovastatin in the conservative treatment of this disorder is discussed.
No takes yet. Share an insight, caveat, or question.
Cabili et al. (1993) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: